尼莫司汀对复发恶性胶质瘤化疗的临床观察

目的:探讨尼莫司汀在复发胶质瘤化疗的疗效。方法:回顾性分析接受尼莫司汀化疗的13例复发胶质瘤患者的临床治疗效果、生存时间及不良反应。结果:所有患者均接受超过3个周期的化学治疗,平均完成4.6个化疗周期。随访时间5-26个月,平均随访时间16个月。3个月无进展生存率53.8%;6个月无进展生存率30.8%;12月无进展生存率23.1%。2例出现Ⅲ度骨髓抑制,其余不良反应包括恶心呕吐(6例)和疲倦乏力(9例),经积极治疗后均好转。结论:尼莫司汀为主的化疗方案是复发胶质瘤化疗的有效手段之一,可以显著地延长患者的生命,并不伴有严重的并发症,特别是针对前期进行过TMZ化疗的病例,具有价格低廉,疗效相当的优点,是替莫唑胺治疗之外很好的选择。

Clinical Observation of Chemotherapy with ACNU in Recurrent Glioma

Objective:To investigate the effect of chemotherapy with ACNU on recurrent glioma.Methods:13 patients with recurrent glioma treated with ACNU were retrospectivly analyzed for therapeutic effects, survival time and adverse reactions.Results:All patients received more than three cycles of chemotherapy, with an average of 4.6 cycles. They were averagely followed-up for 16 months (5-26 months). Progression-free survival rates of 3 months, 6 months and 12 months were 53.8%, 30.8% and 23.1%, respectively. Two patients had bone marrow suppression during the course. The other adverse reactions included nausea and vomiting (6 cases) and fatigue (9 cases), and improved after active treatment.Conclusion:Chemotherapy with ACNU is one of the effective methods for recurrent glioma, which can significantly extend the lifetime of patients without serious complications. Patients who received TMZ-based chemotherapy will benefit more fromACNU for its low price and comparable effect, thus, ACNU is a good choice for non-TMZ therapy.